Graham Kelly

Dr Graham Kelly Ph.D

Founder and Non- Executive Director

Graham Kelly is a scientist with 50 years’ experience in drug development in both academic and biotechnology sectors. Graham is the Founder and Executive Chairman of Noxopharm Limited (ASX:NOX), a major shareholder of Nyrada. Graham has also founded two public, listed drug development companies (Novogen Limited, Marshall Edwards Inc), serving variously as Managing Director and Executive Chairman of those companies. Graham holds a PhD from The University of Sydney, and degrees in Science and Veterinary Science from The University of Sydney.